Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.
about
Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors.Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities.Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.Systematic evaluation of immune regulation and modulationCheckpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults.Immune-Related Adverse Events From Immune Checkpoint Inhibitors.Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.Ipilimumab in melanoma.Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case reportPredicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy.Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors.When worlds collide: Th17 and Treg cells in cancer and autoimmunity.Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice.Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors.A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumabClinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimenNephrotoxicity of Cancer Immunotherapies: Past, Present and Future
P2860
Q36260666-2E88F8B1-18EF-4DD6-AE51-ACB1D07E4582Q37312417-E7836052-B2D9-4691-BD88-4E4C565780A2Q37417271-5E78A169-0E0D-401A-8DCC-3897CDEA46F4Q37713498-1D1AFC66-A20B-40F1-9865-C1EAAC8E61CDQ38654099-7DBA6FEB-4774-4254-879A-FD1A88726F1CQ38832640-2A03A2C7-A62C-491B-9664-A75DF2ED85D9Q38884560-DC2C5001-CC08-4B9F-8DAC-7EA86A57E0F8Q38893697-43D81AF8-FD5B-4811-82CB-00DF39E44B3FQ39009781-A4BC895F-2095-4E42-B108-0DB4CDBEB9F8Q39085984-1C3CCB7E-6ADB-4FB1-B68B-5B42FD69586DQ39369955-E8939A92-D629-4B37-BB6B-0CC0141A48E8Q41018488-5ACA0F03-8072-4B3E-9E4B-BE9D0B929569Q41899044-6D92C98D-FE28-4076-B913-C8921878FC3DQ42369277-8DC42FF5-B9AE-476B-A73B-2E779B0CEFBFQ47854770-C315A572-F3E6-4959-B8DE-D68DE10E2DBFQ48369113-338CB543-2BA9-42CB-AFB1-974BD9E8E8ECQ52615452-69693AE0-E247-4293-911B-905458E6D99BQ52689973-0D99B1F8-8F4F-489D-B21D-1FF9B6CC7AE3Q53695267-124F7297-2DE0-4AF8-B8D0-76614A6B63A5Q55314300-6B9C60A1-C6EA-42AA-BD31-1973982CD50FQ56888756-81250948-6BAD-447F-BB86-31772B0441ADQ56892765-A76D52DB-CC7B-4A80-90E1-10F0336AB732Q57172529-2FEC3877-85E8-4ECA-8D2B-84F52A84142C
P2860
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Baseline circulating IL-17 pre ...... oadjuvant therapy of melanoma.
@ast
Baseline circulating IL-17 pre ...... oadjuvant therapy of melanoma.
@en
type
label
Baseline circulating IL-17 pre ...... oadjuvant therapy of melanoma.
@ast
Baseline circulating IL-17 pre ...... oadjuvant therapy of melanoma.
@en
prefLabel
Baseline circulating IL-17 pre ...... oadjuvant therapy of melanoma.
@ast
Baseline circulating IL-17 pre ...... oadjuvant therapy of melanoma.
@en
P2093
P2860
P1476
Baseline circulating IL-17 pre ...... oadjuvant therapy of melanoma.
@en
P2093
Ahmad A Tarhini
Cindy Sander
Haris Zahoor
John M Kirkwood
Usha Malhotra
P2860
P2888
P356
10.1186/S40425-015-0081-1
P577
2015-09-15T00:00:00Z
P5875
P6179
1036424463